Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
August 02 2023 - 8:00AM
Business Wire
- Webcast to be held Wednesday, August 9, 4:30 p.m. ET, register
here, or at the link below.
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence
(“AI”) company developing targeted and transformative cancer
therapies using its proprietary RADR® AI and machine learning
(“ML”) platform with multiple clinical stage drug programs, today
announced that it will host its second quarter 2023 operating and
financial results webcast on Wednesday, August 9, 4:30 p.m. Eastern
Time / 1:30 p.m. Pacific Time.
Management intends to discuss the operating and financial
results for the second quarter ended June 30, 2023 and provide
guidance on upcoming milestones. Panna Sharma, President and Chief
Executive Officer of Lantern Pharma, will lead the call and will be
joined by other members of the management team.
To register for the webcast, sign up at the link below:
https://us06web.zoom.us/webinar/register/1016902973506/WN_h4QZ0ZyxR3mZZbNQxa2eMw
A replay of the webcast will be available after the call on the
investor relations section of the Company's website at
ir.lanternpharma.com.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the
cost, pace, and timeline of oncology drug discovery and
development. Our proprietary AI and machine learning (ML) platform,
RADR®, leverages over 25 billion oncology-focused data points and a
library of 200+ advanced ML algorithms to help solve
billion-dollar, real-world problems in oncology drug development.
By harnessing the power of AI and with input from world-class
scientific advisors and collaborators, we have accelerated the
development of our growing pipeline of therapies including eleven
cancer indications and an antibody-drug conjugate (ADC) program. On
average, our newly developed drug programs have been advanced from
initial AI insights to first-in-human clinical trials in 2-3 years
and at approximately $1.0-2.0 million per program.
Our lead development programs include two Phase 2 clinical
programs and multiple upcoming Phase 1 clinical trials anticipated
for 2023. We have also established a wholly-owned subsidiary,
Starlight Therapeutics Inc., to focus exclusively on the clinical
execution of our promising therapies for CNS and brain cancers,
many of which have no effective treatment options. Our AI-driven
pipeline of innovative product candidates is estimated to have a
combined annual market potential of over $15 billion USD and have
the potential to provide life-changing therapies to hundreds of
thousands of cancer patients across the world.
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter/X: @lanternpharma Lantern Pharma Newsletter – The Spark:
Sign-up here
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the risk that our research
and the research of our collaborators may not be successful, (ii)
the risk that none of our product candidates has received FDA
marketing approval, and we may not be able to successfully
initiate, conduct, or conclude clinical testing for or obtain
marketing approval for our product candidates, (iii) the risk that
no drug product based on our proprietary RADR® AI platform has
received FDA marketing approval or otherwise been incorporated into
a commercial product, and (iv) those other factors set forth in the
Risk Factors section in our Annual Report on Form 10-K for the year
ended December 31, 2022, filed with the Securities and Exchange
Commission on March 20, 2023. You may access our Annual Report on
Form 10-K for the year ended December 31, 2022 under the investor
SEC filings tab of our website at www.lanternpharma.com or on the
SEC's website at www.sec.gov. Given these risks and uncertainties,
we can give no assurances that our forward-looking statements will
prove to be accurate, or that any other results or events projected
or contemplated by our forward-looking statements will in fact
occur, and we caution investors not to place undue reliance on
these statements. All forward-looking statements in this press
release represent our judgment as of the date hereof, and, except
as otherwise required by law, we disclaim any obligation to update
any forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230802966280/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Apr 2023 to Apr 2024